VESPULA THERAPEUTICS LTD

Company Registration Number:
15191029 (England and Wales)

Unaudited abridged accounts for the year ended 31 October 2025

Period of accounts

Start date: 05 October 2023

End date: 31 October 2025

VESPULA THERAPEUTICS LTD

Contents of the Financial Statements

for the Period Ended 31 October 2025

Balance sheet
Notes

VESPULA THERAPEUTICS LTD

Balance sheet

As at 31 October 2025


Notes
25 months to 31 October 2025


£
Called up share capital not paid: 0
Fixed assets
Intangible assets: 3 416,300
Tangible assets:   0
Investments:   0
Total fixed assets: 416,300
Current assets
Stocks: 0
Debtors:   0
Cash at bank and in hand: 138,167
Investments:   0
Total current assets: 138,167
Creditors: amounts falling due within one year: 4 (33,587)
Net current assets (liabilities): 104,580
Total assets less current liabilities: 520,880
Creditors: amounts falling due after more than one year: 5 (1,134,388)
Provision for liabilities: 0
Total net assets (liabilities): (613,508)
Capital and reserves
Called up share capital: 3
Share premium account: 0
Revaluation reserve:6(59,651)
Other reserves: 0
Profit and loss account: (553,860)
Shareholders funds: (613,508)

The notes form part of these financial statements

VESPULA THERAPEUTICS LTD

Balance sheet statements

For the year ending 31 October 2025 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with Section 444(2A).

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The directors have chosen to not file a copy of the company’s profit & loss account.

This report was approved by the board of directors on 22 July 2026
and signed on behalf of the board by:

Name: Vasily Fedorin
Status: Director

The notes form part of these financial statements

VESPULA THERAPEUTICS LTD

Notes to the Financial Statements

for the Period Ended 31 October 2025

1. Accounting policies

These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

VESPULA THERAPEUTICS LTD

Notes to the Financial Statements

for the Period Ended 31 October 2025

2. Employees

25 months to 31 October 2025
Average number of employees during the period 0

VESPULA THERAPEUTICS LTD

Notes to the Financial Statements

for the Period Ended 31 October 2025

3. Intangible Assets

Total
Cost £
Additions 416,300
Disposals 0
Revaluations 0
Transfers 0
At 31 October 2025 416,300
Amortisation
Charge for year 0
On disposals 0
Other adjustments 0
At 31 October 2025 0
Net book value
At 31 October 2025 416,300

VESPULA THERAPEUTICS LTD

Notes to the Financial Statements

for the Period Ended 31 October 2025

4. Creditors: amounts falling due within one year note

Suspense account

VESPULA THERAPEUTICS LTD

Notes to the Financial Statements

for the Period Ended 31 October 2025

5. Creditors: amounts falling due after more than one year note

Loan from 4BIO Ventures II

VESPULA THERAPEUTICS LTD

Notes to the Financial Statements

for the Period Ended 31 October 2025

6. Revaluation reserve

25 months to 31 October 2025
£
Surplus or deficit after revaluation (59,651)
Balance at 31 October 2025 (59,651)